Table 1.
Clinical characteristics.
| Number of patients | 652 |
| Median Age at biopsy (yr)(IQR) | 62.8 (58, 67) |
| Median total PSA before biopsy (ng/mL) (IQR) | 8.9 (6.5, 12.6) |
| Median Number of cores taken (IQR) | 29 (25, 34) |
| Mean NLR (SD) | 2.22 (1.13) |
| Median Neutrophil count (IQR) | 3.65 (3.01, 4.45) |
| Median Lymphocyte count (IQR) | 1.89 (1.47, 2.28) |
| Prostate volume (ml; Mean ± SD) | |
| Overall | 38.8 ± 15.8 |
| Benign | 41.3 ± 0.80 |
| Prostate cancer | 34.6 ± 0.97 |
| Histology: | |
| Benign | 409 |
| Prostate cancer | 243 |
| Gleason score 6 and below (Grade 1) | 111 (45.7%) |
| Gleason score 7 (3 + 4) (Grade 2) | 65 (26.7%) |
| Gleason score 7 (4 + 3) (Grade 3) | 34 (14.0%) |
| Gleason score 8 (Grade 4) | 26 (10.7%) |
| Gleason score 9 (Grade 5) | 7 (2.9%) |
| Clinical staging: | |
| cT1-T2 | 229 (94.2%) |
| cT3 | 14 (5.8%) |
| D’Amico risk classification | |
| Low risk | 73 (30.0%) |
| Intermediate risk | 91 (37.4%) |
| High risk | 79 (32.6%) |
| Biopsy naïve | 176 (27.0%) |
| Previous negative biopsy | 476 (73.0%) |
IQR = interquartile range, SD = standard deviation.